{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:28:34Z","timestamp":1761535714932,"version":"build-2065373602"},"reference-count":11,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,6]],"date-time":"2022-11-06T00:00:00Z","timestamp":1667692800000},"content-version":"vor","delay-in-days":735,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1111\/jth.15077","type":"journal-article","created":{"date-parts":[[2020,10,29]],"date-time":"2020-10-29T09:21:17Z","timestamp":1603963277000},"page":"2826-2827","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Commentary on: First\u2010in\u2010patient study of hetrombopag in patients with chronic idiopathic thrombocytopenic purpura"],"prefix":"10.1016","volume":"18","author":[{"given":"David","family":"G\u00f3mez\u2010Almaguer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1111\/jth.15077_bb0010","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.3324\/haematol.2018.212845","article-title":"Thrombopoietin receptor agonists: ten years later","volume":"104","author":"Ghanima","year":"2019","journal-title":"Haematologica"},{"key":"10.1111\/jth.15077_bb0015","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.hoc.2009.09.001","article-title":"Thrombopoietin and platelet production in chronic immune thrombocytopenia","volume":"23","author":"Kuter","year":"2009","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1111\/jth.15077_bb0020","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1038\/sj.onc.1205323","article-title":"The molecular and cellular biology of thrombopoietin: the primary regulator of platelet production","volume":"21","author":"Kaushansky","year":"2002","journal-title":"Oncogene"},{"key":"10.1111\/jth.15077_bb0025","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1182\/bloodadvances.2019000812","article-title":"Updated international consensus report on the investigation and management of primary immune thrombocytopenia","volume":"3","author":"Provan","year":"2019","journal-title":"Blood Adv"},{"key":"10.1111\/jth.15077_bb0030","unstructured":"Drug Trial Snapshot: MULPLETA|FDA [Internet]. [cited 2020 Aug 13]. https:\/\/www.fda.gov\/drugs\/drug\u2010approvals\u2010and\u2010databases\/drug\u2010trial\u2010snapshot\u2010mulpleta"},{"key":"10.1111\/jth.15077_bb0035","unstructured":"Drug Trial Snapshot: Doptelet|FDA [Internet]. [cited 2020 Aug 13]. https:\/\/www.fda.gov\/drugs\/drug\u2010approvals\u2010and\u2010databases\/drug\u2010trial\u2010snapshot\u2010doptelet"},{"key":"10.1111\/jth.15077_bb0040","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/bcpt.12815","article-title":"Safety, pharmacokinetics and pharmacodynamics of hetrombopag olamine, a novel TPO\u2010R agonist, in healthy individuals","volume":"121","author":"Zheng","year":"2017","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1111\/jth.15077_bb0045","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1111\/bcp.14259","article-title":"Effect of postdose fasting duration on hetrombopag olamine pharmacokinetics and pharmacodynamics in healthy volunteers","volume":"86","author":"Yang","year":"2020","journal-title":"Br J Clin Pharmacol"},{"key":"10.1111\/jth.15077_bb0050","doi-asserted-by":"crossref","DOI":"10.1111\/jth.15078","article-title":"First\u2010in\u2010patient study of hemotrombopag in patients with chronic idiopathic thrombocytopenic purpura","author":"Wang","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.15077_bb0055","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1016\/j.clinthera.2015.03.024","article-title":"Population pharmacokinetic and pharmacodynamic modeling and effects on platelet counts of different dosages of eltrombopag in Chinese patients with chronic primary immune thrombocytopenia","volume":"37","author":"Wu","year":"2015","journal-title":"Clin Ther"},{"key":"10.1111\/jth.15077_bb0060","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/j.1538-7836.2012.04695.x","article-title":"A lower starting dose of eltrombopag is efficacious in Japanese patients with previously treated chronic immune thrombocytopenia","volume":"10","author":"Tomiyama","year":"2012","journal-title":"J Thromb Haemost"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jth.15077","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jth.15077","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S153878362203745X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S153878362203745X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jth.15077","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:26:06Z","timestamp":1761535566000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S153878362203745X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":11,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S153878362203745X"],"URL":"https:\/\/doi.org\/10.1111\/jth.15077","relation":{},"ISSN":["1538-7836"],"issn-type":[{"type":"print","value":"1538-7836"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Commentary on: First\u2010in\u2010patient study of hetrombopag in patients with chronic idiopathic thrombocytopenic purpura","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/jth.15077","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2020 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}